{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:24Z","timestamp":1787169504290,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00432-022-04067-1","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:18:59Z","timestamp":1655896739000},"page":"2383-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study"],"prefix":"10.1007","volume":"149","author":[{"given":"Lan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuna","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"4067_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.leukres.2011.11.018","volume":"36","author":"CL Andersen","year":"2012","unstructured":"Andersen CL, Hasselbalch H, Gr\u00f8nb\u00e6k K (2012) Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. Leuk Res 36:485\u2013487. https:\/\/doi.org\/10.1016\/j.leukres.2011.11.018","journal-title":"Leuk Res"},{"key":"4067_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"4067_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s1462399407000336","volume":"9","author":"S Ariyaratana","year":"2007","unstructured":"Ariyaratana S, Loeb DM (2007) The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 9:1\u201317. https:\/\/doi.org\/10.1017\/s1462399407000336","journal-title":"Expert Rev Mol Med"},{"key":"4067_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026534","author":"N Attar","year":"2017","unstructured":"Attar N, Kurdistani SK (2017) Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026534","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4067_CR5","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/jco.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:3179\u20133184. https:\/\/doi.org\/10.1200\/jco.2010.34.5298","journal-title":"J Clin Oncol"},{"key":"4067_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.24288","volume":"91","author":"T Barbui","year":"2016","unstructured":"Barbui T, Thiele J, Vannucchi AM et al (2016) Myeloproliferative neoplasms: morphology and clinical practice. Am J Hematol 91:430\u2013433. https:\/\/doi.org\/10.1002\/ajh.24288","journal-title":"Am J Hematol"},{"key":"4067_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8:15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"key":"4067_CR8","doi-asserted-by":"publisher","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","volume":"7","author":"G Barosi","year":"2012","unstructured":"Barosi G, Rosti V, Bonetti E et al (2012) Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS ONE 7:e35631. https:\/\/doi.org\/10.1371\/journal.pone.0035631","journal-title":"PLoS ONE"},{"key":"4067_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/jhep.2003.50269","volume":"38","author":"C Berasain","year":"2003","unstructured":"Berasain C, Herrero JI, Garc\u00eda-Trevijano ER et al (2003) Expression of Wilms\u2019 tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology 38:148\u2013157. https:\/\/doi.org\/10.1053\/jhep.2003.50269","journal-title":"Hepatology"},{"key":"4067_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M et al (2019) T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med 25:1064\u20131072. https:\/\/doi.org\/10.1038\/s41591-019-0472-9","journal-title":"Nat Med"},{"key":"4067_CR11","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/jco.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F et al (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27:5195\u20135201. https:\/\/doi.org\/10.1200\/jco.2009.22.4865","journal-title":"J Clin Oncol"},{"key":"4067_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bcmd.2018.12.004","volume":"75","author":"L Cottin","year":"2019","unstructured":"Cottin L, Riou J, Boyer F et al (2019) WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells Mol Dis 75:35\u201340. https:\/\/doi.org\/10.1016\/j.bcmd.2018.12.004","journal-title":"Blood Cells Mol Dis"},{"key":"4067_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ejh.13236","volume":"102","author":"Y Edahiro","year":"2019","unstructured":"Edahiro Y, Araki M, Inano T et al (2019) Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol 102:516\u2013520. https:\/\/doi.org\/10.1111\/ejh.13236","journal-title":"Eur J Haematol"},{"key":"4067_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/cam4.735","volume":"5","author":"D Gallo","year":"2016","unstructured":"Gallo D, Nicoli P, Calabrese C et al (2016) The Wilms\u2019 tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is. Cancer Med 5:1650\u20131653. https:\/\/doi.org\/10.1002\/cam4.735","journal-title":"Cancer Med"},{"key":"4067_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0895-4356(94)90195-3","volume":"47","author":"RF Gillum","year":"1994","unstructured":"Gillum RF, Mussolino ME (1994) White blood cell count and hypertension incidence. The NHANES I epidemiologic follow-up study. J Clin Epidemiol 47:911\u2013919. https:\/\/doi.org\/10.1016\/0895-4356(94)90195-3","journal-title":"J Clin Epidemiol"},{"key":"4067_CR16","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 129:3227\u20133236. https:\/\/doi.org\/10.1182\/blood-2017-01-761999","journal-title":"Blood"},{"key":"4067_CR17","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1073\/pnas.88.21.9618","volume":"88","author":"DA Haber","year":"1991","unstructured":"Haber DA, Sohn RL, Buckler AJ et al (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88:9618\u20139622. https:\/\/doi.org\/10.1073\/pnas.88.21.9618","journal-title":"Proc Natl Acad Sci USA"},{"key":"4067_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","volume":"6","author":"YH Huang","year":"2021","unstructured":"Huang YH, Cai K, Xu PP et al (2021) CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduct Target Ther 6:10. https:\/\/doi.org\/10.1038\/s41392-020-00437-8","journal-title":"Signal Transduct Target Ther"},{"key":"4067_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","volume":"37","author":"K Hussein","year":"2009","unstructured":"Hussein K, Bock O, Theophile K et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37:1186-1193.e1187. https:\/\/doi.org\/10.1016\/j.exphem.2009.07.005","journal-title":"Exp Hematol"},{"key":"4067_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B et al (2017) Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol 92:885\u2013891. https:\/\/doi.org\/10.1002\/ajh.24788","journal-title":"Am J Hematol"},{"key":"4067_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","volume":"51","author":"SN Meyer","year":"2019","unstructured":"Meyer SN, Scuoppo C, Vlasevska S et al (2019) Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity 51:535-547.e539. https:\/\/doi.org\/10.1016\/j.immuni.2019.08.006","journal-title":"Immunity"},{"key":"4067_CR22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bjh.14838","volume":"182","author":"M Mudireddy","year":"2018","unstructured":"Mudireddy M, Shah S, Lasho T et al (2018) Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. Br J Haematol 182:594\u2013597. https:\/\/doi.org\/10.1111\/bjh.14838","journal-title":"Br J Haematol"},{"key":"4067_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-pathol-011811-132434","volume":"7","author":"AG Muntean","year":"2012","unstructured":"Muntean AG, Hess JL (2012) The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 7:283\u2013301. https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132434","journal-title":"Annu Rev Pathol"},{"key":"4067_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2015.87","volume":"29","author":"F Palandri","year":"2015","unstructured":"Palandri F, Latagliata R, Polverelli N et al (2015) Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia 29:1344\u20131349. https:\/\/doi.org\/10.1038\/leu.2015.87","journal-title":"Leukemia"},{"key":"4067_CR25","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","volume":"33","author":"KA Rack","year":"2019","unstructured":"Rack KA, van den Berg E, Haferlach C et al (2019) European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia 33:1851\u20131867. https:\/\/doi.org\/10.1038\/s41375-019-0378-z","journal-title":"Leukemia"},{"key":"4067_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ajh.22216","volume":"87","author":"S Raza","year":"2012","unstructured":"Raza S, Viswanatha D, Frederick L et al (2012) TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol 87:204\u2013206. https:\/\/doi.org\/10.1002\/ajh.22216","journal-title":"Am J Hematol"},{"key":"4067_CR27","doi-asserted-by":"publisher","first-page":"101735","DOI":"10.18632\/oncotarget.21594","volume":"8","author":"E Rumi","year":"2017","unstructured":"Rumi E, Boveri E, Bellini M et al (2017) Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 8:101735\u2013101744. https:\/\/doi.org\/10.18632\/oncotarget.21594","journal-title":"Oncotarget"},{"key":"4067_CR28","doi-asserted-by":"publisher","first-page":"15873","DOI":"10.1038\/s41598-018-33881-2","volume":"8","author":"M Saika","year":"2018","unstructured":"Saika M, Inoue D, Nagase R et al (2018) ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGF\u03b2 pathway genes through histone deacetylation. Sci Rep 8:15873. https:\/\/doi.org\/10.1038\/s41598-018-33881-2","journal-title":"Sci Rep"},{"key":"4067_CR29","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1093\/ndt\/gfr061","volume":"26","author":"T Sakairi","year":"2011","unstructured":"Sakairi T, Abe Y, Kopp JB (2011) TGF-beta1 reduces Wilms\u2019 tumor suppressor gene expression in podocytes. Nephrol Dial Transplant 26:2746\u20132752. https:\/\/doi.org\/10.1093\/ndt\/gfr061","journal-title":"Nephrol Dial Transplant"},{"key":"4067_CR30","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1182\/blood-2005-09-3646","volume":"107","author":"DP Steensma","year":"2006","unstructured":"Steensma DP, Pardanani A, Stevenson WS et al (2006) More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Blood 107:1733\u20131735. https:\/\/doi.org\/10.1182\/blood-2005-09-3646 (author reply 1735)","journal-title":"Blood"},{"key":"4067_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95:1599\u20131613. https:\/\/doi.org\/10.1002\/ajh.26008","journal-title":"Am J Hematol"},{"key":"4067_CR32","doi-asserted-by":"publisher","first-page":"11100","DOI":"10.1111\/jcmm.15526","volume":"24","author":"P Teodorescu","year":"2020","unstructured":"Teodorescu P, Pasca S, Jurj A et al (2020) Transforming growth factor \u03b2-mediated micromechanics modulates disease progression in primary myelofibrosis. J Cell Mol Med 24:11100\u201311110. https:\/\/doi.org\/10.1111\/jcmm.15526","journal-title":"J Cell Mol Med"},{"key":"4067_CR33","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, M\u00fcllauer L et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117:5710\u20135718. https:\/\/doi.org\/10.1182\/blood-2010-07-293761","journal-title":"Blood"},{"key":"4067_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24973","volume":"93","author":"G Venton","year":"2018","unstructured":"Venton G, Courtier F, Charbonnier A et al (2018) Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol 93:330\u2013338. https:\/\/doi.org\/10.1002\/ajh.24973","journal-title":"Am J Hematol"},{"key":"4067_CR35","first-page":"312","volume":"43","author":"L Xi","year":"2015","unstructured":"Xi L, Hao Y, Liu J et al (2015) Relationship between leukocyte count and risk of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 43:312\u2013318","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"4067_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/sj.leu.2404624","volume":"21","author":"L Yang","year":"2007","unstructured":"Yang L, Han Y, Suarez Saiz F et al (2007) A tumor suppressor and oncogene: the WT1 story. Leukemia 21:868\u2013876. https:\/\/doi.org\/10.1038\/sj.leu.2404624","journal-title":"Leukemia"},{"key":"4067_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.exphem.2020.07.012","volume":"89","author":"K Young","year":"2020","unstructured":"Young K, Loberg MA, Eudy E et al (2020) Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias. Exp Hematol 89:61-67.e63. https:\/\/doi.org\/10.1016\/j.exphem.2020.07.012","journal-title":"Exp Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04067-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T06:07:28Z","timestamp":1682402848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04067-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4067"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04067-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"8 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Fourth Affiliated Hospital of Zhejiang University School of Medicine. Written informed consent was obtained from all subjects included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}